Finance
Cancer treatment biotech company announces status, 6-month results
Published in Cancer Weekly, October 15th, 2002
Novuspharma SpA (NOV.MI), a biotechnology company focused on cancer, announced financial results for the 6 months ended 30 June 2002 and an update on R&D in the second quarter. Development program for BBR 2778 for non-Hodgkin lymphoma (NHL) progressing well Pivotal phase III study in indolent NHL started with 100 centers being opened worldwide Dose ranging combination studies with standard therapy underway in Europe and the United States to determine optimum dose for efficacy combination studies Preliminary signs of efficacy seen in ongoing phase II studies with BBR 3576 and BBR 3438 in prostate...
Highlights:
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2002-10-15)
More Articles from Cancer Weekly
- Cancer Vaccine
Strategy for treating MUC1-expressing tumors depends upon tumor origin - Hepatocellular Carcinoma
Percutaneous ethanol injection therapy appropriate for use in the elderly - Breast Cancer
Research reveals a more complete picture of breast tissue - Melanoma
New approach to replacing immune cells shrinks tumors in patients - Metastasis
Researchers develop first fully automatic method to track 3-D movement of cancer cells - Prostate Cancer
Heart disease gene link found - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
